Radioactive drug BPA order indicated for positron emission tomography (pet) of prostate-specific membrane antigen (psma) positive lesions in men with prostate cancer with suspected metastasis
Ended Awarded Last action
- Contract number
- 36C26123N0373
- Awardee
-
Progenics Pharmaceuticals Inc. UEI YLYKVRPCTCR3 Part of Lantheus Holdings, Inc.
- Awarding agency
-
Veterans Integrated Service Network 21
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $429,438
Award facts
- Contract value 100% obligated
- $429,437.68 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- North Billerica, Billerica, MA 01862, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$202,088 | |
| Original award | $631,526 |
About this award
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 21 awarded a firm fixed price blanket purchase agreement call valued at four hundred twenty-nine thousand four hundred thirty-seven dollars and sixty-eight cents ($429,437.68) to Progenics Pharmaceuticals Inc., a subsidiary of Lantheus Holdings, Inc., for the delivery of radioactive drugs indicated for positron emission tomography of prostate-specific membrane antigen positive lesions in men with prostate cancer with suspected metastasis. The contract supports the delivery of products through September 2023. Progenics Pharmaceuticals holds multiple blanket purchase agreements with the Department of Veterans Affairs for prostate cancer medications and imaging agents to support cancer detection programs across the agency through 2027. No set-aside designation was applied to this award.
Quick answers
Who was awarded contract 36C26123N0373?
36C26123N0373 was awarded to Progenics Pharmaceuticals Inc. by Veterans Integrated Service Network 21 (Veterans Health Administration) on February 16, 2023.
How much is contract 36C26123N0373 worth?
The government has obligated $429,438 on 36C26123N0373.
Is contract 36C26123N0373 an order under another contract?
Yes. 36C26123N0373 is a BPA call under 36F79719D0170-36C26123A0025, a blanket purchase agreement, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26123N0373 competed?
The extent of competition for 36C26123N0373 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award